Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
ZS and Quartic will collaborate to help drive resilience, increase adoption of Industry 4.0 and improve predictive decision-making across manufacturing
Subscribe To Our Newsletter & Stay Updated
